FDA grants Fast Track designation to Corbus' CRB-701 for cervical cancer

Corbus Pharmaceuticals Holdings, Inc.

CRB-701 is a next-generation Nectin-4 ADC with site-specific cleavable linker, MMAE payload, DAR 2.
Company completed dose-escalation enrollment for Phase 1 trial in US/Europe (NCT06265727).
First clinical data from dose-escalation study expected in Q1 2025.
Fast Track designation aims to speed development and review for unmet medical need in metastatic cervical cancer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.